Outcomes of Intravitreal Bevacizumab Combined with Suprachoroidal Triamcinolone Acetonide in Central Retinal Vein Occlusion with Macular Edema
Purpose: To determine the outcomes of intravitreal Bevacizumab 1.25 mg in 0.05 ml combined with supra-choroidal triamcinolone acetonide 0.05 ml in terms of safety and efficacy, while treating macular edema associated with central retinal vein occlusion (CRVO).
Study Design: Interventional case series.
Place and Duration of Study: This study was conducted at ophthalmology department of Hayatabad medical complex, Peshawar from July 2021 to December 2021.
Methods: Total 34 patients of CRVO with macular edema were included in the study. After complete ocular examination each patient received one injection of intravitreal bevacizumab (1.25 mg/0.05 ml) along with supra-choroidal triamcinolone acetonide (2 mg/0.05 ml), followed by similar monthly injections for two months. Visual acuity and central macular thickness and intra-ocular pressure (IOP) were assessed at presentation and then monthly for 3 months. Visual acuity was measured in Log-MAR, central foveal thickness on SD-OCT and IOP was measured with Goldmann Applanation Tonometer. The data was analyzed using SPSS version 24. For comparison of means, the paired-t test was used. A significance level of <0.05 was set for significance.
Results: There were 22 (64.7%) males and 12 (35.5%) females. Mean age of the patients was 53.18 ± 13.39 years. Central foveal thickness decreased significantly at 3 months post treatment (p ˂ 0.001). Visual acuity also significantly increased from presentation to 3rd month post treatment (p ˂ 0.001), and the intra-ocular pressure remained within normal range from presentation to 3rd month post treatment.
Conclusion: Both supra-choroidal triamcinolone acetonide and intravitreal bevacizumab are safe and effective in the treatment of macular edema secondary to CRVO.
How to Cite
Copyright (c) 2023 Salahuddin, Sanaullah Jan, Yousaf Jamal Mahsood, Tariq Shahnam, Ziauddin Khalil, Ahmad Jamal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.